Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Breast Neoplasms 2Uterine Neoplasms 1Uterine Cervical Neoplasms 1Pseudomyxoma Peritonei 1Lymphoma, B-Cell, Marginal Zone 1Leukemia, B-Cell 1Endometrial Neoplasms 1Appendiceal Neoplasms 1

Interventions

Mitomycin 6Hyperthermic Intraperitoneal Chemotherapy 3Oxaliplatin 2Melphalan 2Leucovorin 2surufatinib 1sintilimab 1nintedanib 1nilotinib 1Thalidomide 1Surgical Procedures, Operative 1Palonosetron 1Paclitaxel 1Laparoscopy 1Lansoprazole 1Irinotecan 1Fluorouracil 1Floxuridine 1Electrocardiography 1Drug Therapy 1Cytoreduction Surgical Procedures 1Cryotherapy 1Clarithromycin 1Capecitabine 1Amoxicillin 1Acupuncture Therapy 1Acupressure 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Appendiceal Neoplasms × Lansoprazole × Clear all
NCT02387203 2024-11-19

Antibiotic Treatment and Long-term Outcomes of Patients With Pseudomyxoma Peritonei of Appendiceal Origin

Mercy Medical Center

Phase 2 Active not recruiting
80 enrolled
Gastrointestinal

Appendiceal Neoplasms, Pseudomyxoma Peritonei

Data powered by HemOnc (CC BY 4.0) Colophon âš¡